Clene (CLNN)
(Delayed Data from NSDQ)
$3.67 USD
+0.01 (0.27%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $3.68 +0.01 (0.27%) 4:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLNN 3.67 +0.01(0.27%)
Will CLNN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLNN
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Other News for CLNN
Clene to Present at the Canaccord 45th Annual Growth Conference | CLNN Stock News
Clene (CLNN) Receives Consistent Buy Rating from D. Boral Capital | CLNN Stock News
12 Health Care Stocks Moving In Friday's After-Market Session
Clene (CLNN) Maintains "Buy" Rating with $23 Price Target | CLNN Stock News
Clene provides regulatory update following FDA Type C meeting